Browse MEIS2

Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm, perinuclear region
Domain PF05920 Homeobox KN domain
PF16493 N-terminal of Homeobox Meis and PKNOX1
Function

Involved in transcriptional regulation. Binds to HOX or PBX proteins to form dimers, or to a DNA-bound dimer of PBX and HOX proteins and thought to have a role in stabilization of the homeoprotein-DNA complex. Isoform 3 is required for the activity of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element; MEIS2 is not involved in complex DNA-binding. Probably in complex with PBX1, is involved in transcriptional regulation by KLF4. Isoform 3 and isoform 4 can bind to a EPHA8 promoter sequence containing the DNA motif 5'-CGGTCA-3'; in cooperation with a PBX protein (such as PBX2) is proposed to be involved in the transcriptional activation of EPHA8 in the developing midbrain. May be involved in regulation of myeloid differentiation. Can bind to the DNA sequence 5'-TGACAG-3'in the activator ACT sequence of the D(1A) dopamine receptor (DRD1) promoter and activate DRD1 transcription; isoform 5 cannot activate DRD1 transcription.

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0002683 negative regulation of immune system process
GO:0007423 sensory organ development
GO:0007611 learning or memory
GO:0007612 learning
GO:0007632 visual behavior
GO:0008306 associative learning
GO:0008542 visual learning
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0009612 response to mechanical stimulus
GO:0030099 myeloid cell differentiation
GO:0031016 pancreas development
GO:0044708 single-organism behavior
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0050890 cognition
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003714 transcription corepressor activity
GO:0008134 transcription factor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MEIS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MEIS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MEIS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.020.0084
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1720.428
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.9140.384
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4420.271
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1890.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2480.663
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5790.146
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1010.933
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.2870.355
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4750.635
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3210.331
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2690.012
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MEIS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MEIS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MEIS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MEIS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MEIS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MEIS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MEIS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMEIS2
NameMeis homeobox 2
Aliases HsT18361; Meis (mouse) homolog 2; Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse); Meis ......
Chromosomal Location15q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MEIS2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.